Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum. This takes time, but patient investors could score a major win by following Wood's strategy -- and by picking up a couple of her favorite stocks.Over the past several weeks, Wood has added to one of her key positions, a stock that's lost about 20% this year. This particular player is the second-biggest holding in Wood's healthcare fund and among the top 10 positions in her flagship Ark Innovation fund. The company late last year scored its first product approval and proved the efficacy of its potentially game-changing technology.Meet the beaten-down biotech that Wood loves and Wall Street says may soar more than 65% over the coming 12 months.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool